As part of the restructuring of AECL led by the Government of Canada, the assets of AECL’s CANDU Reactor Division were sold to Candu Energy Inc.
The National Research Experimental Reactor (NRU) shuts down unexpectedly, putting the spotlight on AECL’s role in the production and supply of medical isotopes
On May 15, 2009, a heavy-water leak was detected within the NRU facility. At the time, the reactor was quietly producing 30 per cent of the world’s supply of a key medical isotope used in the treatment and diagnostic of cancer and other diseases, Molybdenum-99m. The shutdown left researchers and medical professionals searching for supply from the world’s four other producing reactors, before the NRU was put back in service in March 2010.
As part of the second phase of the restructuring of AECL, CNL was launched in 2014.